Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Pemvidutide demonstrated a favorable safety profile in the MOMENTUM trial
If they're going on it in the short term and having all these side effects and having to go off, then they're kind of all over the place, maybe not being as well managed as if they were on one medication consistently that was working
Studies indicate that approximately 20-30% of patients experience nausea when starting treatment with GLP-1 agonists, especially during the initial titration period
The parameters measured were glucose tolerance, endogenous secretory patterns of the proglucagon-derived hormones GLP-1, glucagon, and glicentin, as well as insulin, proinsulin, C-peptide and the enzyme dipeptidyl peptidase-4 (DPP-4)
